Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 Congress
Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 Congress
- Sub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristics
- Longer-term data from Kite’s ZUMA-2 study of CAR T cell therapy in relapsed/refractory mantle cell lymphoma
- Phase 1b results for investigational anti-CD47 antibody in advanced myelodysplastic syndromes and acute myeloid leukaemia
“Many patients with the most difficult-to-treat blood cancers face the greatest gaps in care, and Gilead’s deep and diverse development program in haematologic malignancies is designed to address this need,” said Mike Elliot, Vice President, Medical Affairs, Australia, Canada and Europe, Gilead. “Our research explores the use of our investigational anti-CD47 antibody and CAR T cell therapies across lymphomas, leukaemias and other underserved diseases such as myelodysplastic syndromes at this year's EHA Congress.”
Phase 1b Study 005: Magrolimab
Results of a multi-cohort study evaluating an investigational anti-CD47 antibody in combination with azacitidine in higher-risk myelodysplastic syndromes and in acute myeloid leukaemia.
“Kite’s research at EHA reflects our commitment to expanding the potential of cell therapy across different blood cancers and lines of treatment,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe (ACE), Kite. “Important data for our investigational CAR T cell therapy in second-line diffuse large B cell lymphoma examines areas of unmet need, such as patients over 65 years old, and these are complemented by long-term follow-up results in relapsed/refractory mantle cell lymphoma that reinforce the strength of our therapy.”
ZUMA-7: Axicabtagene Ciloleucel
Sub-analyses of Phase 3 ZUMA-7 study of axicabtagene ciloleucel as second-line therapy in relapsed/refractory diffuse large B cell lymphoma, including in patients over 65 and by tumour burden characteristics, and patient-reported outcomes.
ZUMA-2: Brexucabtagene Autoleucel
Three-year follow-up results from the pivotal ZUMA-2 trial of brexucabtagene autoleucel (Tecartus®) in patients with relapsed/refractory mantle cell lymphoma.
ZUMA-3: Brexucabtagene Autoleucel
Sub-analyses of the ZUMA-3 study of brexucabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia by prior number of therapy lines, including blinatumomab and allogeneic stem cell transplant (alloSCT), and subsequent alloSCT.
Abstracts published at the meeting will include:
|
Study Name and Session Information |
Abstract Title Primary Author |
|
B-cell Lymphomas |
|
|
ZUMA-7 Age ≥65 (including PRO) Analysis Encore Abstract Number: S211 Saturday 11 June 2022, 11:30 AM-12:45 CEST, Hall A7 |
Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel(axi-cel) vs standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) (ZUMA-7) Anna Sureda, Jason Westin, Olalekan Oluwole et al. |
|
ZUMA-7 Tumor Burden Encore Abstract Number: P1198 Friday 10 June 2022, 16:30-17:45 CEST |
Association Of Pretreatment Tumor Characteristics And Clinical Outcomes Following Second-Line Axicabtagene Ciloleucel Vs Standard Of Care In Patients With Relapsed/Refractory Large B-Cell Lymphoma Pier L. Zinzani, Frederick L. Locke, Jérôme Galon et al. |
|
ZUMA-14 Cohort 1 Encore Abstract Number: P1197 Friday 10 June 2022, 16:30-17:45 CEST |
Axicabtagene Ciloleucel (Axi-Cel) In Combination With Rituximab For The Treatment Of Relapsed/Refractory (R/R) Large B-Cell Lymphoma (Lbcl): Outcomes Of The Phase 2 ZUMA-14 Study Paolo Strati, Lori Leslie, Krish Patel et al.
|
|
Mantle Cell Lymphoma (MCL) |
|
|
ZUMA-2 Three-year Follow-up Encore Abstract Number: P1117 Friday 10 June 2022, 16:30-17:45 CEST |
Three-Year Follow-up of Outcomes With KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma in ZUMA-2 Michael Wang, Javier Munoz, Patrick M. Reagan et al.
|
|
HEOR: ZUMA-2 Cost-Effectiveness Analysis of Tecartus vs SoC (Italian) Abstract Number: S302 Saturday 11 June 2022, 11:30 AM-12:45 CEST |
Cost-Effectiveness Of KTE-X19 In Patients With Relapsed/Refractory Mantle Cell Lymphoma Monia Marchetti and Carlo Visco
|
|
Real World Evidence: MCL Abstract Number: P1454 Friday 10 June 2022, 16:30-17:45 CEST |
Real-World Outcomes Of Brexucabtagene Autoleucel (Brexu-Cel) For The Treatment Of Relapsed Or Refractory (R/R) Mantle Cell Lymphoma (MCL) In The United States (US) Frederick Locke, Zhen-Huan Hu, Marcelo Pasquini et al. |
|
Acute Lymphoblastic Leukaemia (ALL) |
|
|
ZUMA-3 Treatment Subgroup Analyses Abstract Number: P356 Friday 10 June 2022, 16:30-17:45 CEST |
Subgroup Analyses Of KTE-X19, An Anti-Cd19 Chimeric Antigen Receptor (Car) T-Cell Therapy, In Adult Patients With Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-All) In ZUMA-3 Bijal Shah, Ryan Cassaday, Armin Ghobadi et al. |
|
Myelodysplastic Syndromes (MDS) |
|
|
Phase 1b Study: MDS Abstract Number: S166 Sunday 12 June, 11:30 - 12:45 CEST |
Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 Phase 1b study results David A. Sallman, Monzr M Al Malki, Naval Daver et al. |
|
Red Blood Cell Pruning Abstract Number: P740 Friday 10 June, 16:30 - 17:45 CEST |
Impact of magrolimab treatment in combination with azacitidine on red blood cells in higher-risk myelodysplastic syndrome (HR-MDS) patients James Y. Chen, Natalia Garcia-Martin, Irving Weissman et al. |
|
MDS Literature Review Abstract Number: P774 Friday 10 June, 16:30 - 17:45 CEST |
Clinical outcomes associated with azacitidine monotherapy for treatment-naïve higher-risk myelodysplastic syndrome: A systematic literature review and meta-analysis Ken Hasegawa, Preston Tse, David A Sallman et al. |
|
Real World Evidence: Higher-Risk MDS Abstract Number: PB1922 |
Effectiveness of azacitidine in frontline higher-risk myelodysplastic syndrome (HR MDS): a retrospective cohort study of 382 patients Nishanthan Rajakumaraswamy, Mitul Gandhi, Paresh Vyas et al. |
|
Acute Myeloid Leukaemia (AML) |
|
|
Phase 1b Study: AML Abstract Number: S132 Friday 10 June, 11:30 - 12:45 CEST |
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results Naval Daver, Paresh Vyas, David Sallman et al. |
|
AML Literature Review Abstract Number: P552 Friday 10 June, 16:30 - 17:45 CEST |
Treatment outcomes for newly diagnosed, untreated TP53-mutated acute myeloid leukemia: A systematic review and meta-analysis Naval Daver, Shahed Iqbal, Michael J Zoratti et al. |
|
Phase 3 Study: TP53-Mutant AML (TiP) Abstract Number: P551 Friday 10 June, 16:30 - 17:45 CEST |
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia Naval G Daver, Paresh Vyas, Andrew H Wei et al. |
|
Phase 2 Study: AML (TiP) Abstract Number: P553 Friday 10 June, 16:30 - 17:45 CEST |
A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia Paresh Vyas, Naval Daver, David A Sallman et al. |
|
Phase 3 Study: First-line AML (TiP) Abstract Number: P550 Friday 10 June, 16:30 - 17:45 CEST |
A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3) Naval Daver, Paresh Vyas et al. |
|
Multiple Myeloma (MM) |
|
|
Phase 2 Study: MM (TiP) Abstract Number: PB2012 |
A Phase 2 Multiarm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma Barry Paul, Michaela Liedtke, Saad Z Usmani et al. |
The following Gilead and Kite spokespeople will be available:
- Mike Elliot, Vice President, Medical Affairs, Australia, Canada and Europe, Gilead
- Dick Sundh, Vice President, Head of ACE, Kite
- Dominique Tonelli, Head of Medical Affairs, ACE, Kite
For more information or to arrange an interview, contact:
- Marian Cutler, Media Gilead Global (+1 973 517 0519 or marian.cutler1@gilead.com)
- Cressida Robson, Media Kite ACE (+44 7341 789 204 or cressida.robson@kitepharma.com)
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
